Wanis' remarks came his address at the third edition of Al-Ahram Establishment’s pharmaceutical conference that was held over two days and concluded on Monday.
“Egypt's Vision 2030 aims at extending integrated healthcare to all Egyptians, which aligns with Bayer’s vision and its slogan Health for All, Hunger for None," Wanis pointed out.
Bayer is a world-leading company in healthcare that has operated in the Egyptian market for over 90 years with a main objective of providing the best approved treatments for patients in a sustainable manner, he added.
“This is achieved through the localisation of the pharma industry. In this respect, Bayer started its journey in Egypt in 1996 by producing one of the antibiotics in all its concentrations, which makes EGP 21 million in sales at the present time,” he noted.
Bayer started localising aspirin manufacturing in the Egyptian market in 2010 with total sales of EGP 280 million, he said, adding that one of the company’s anti-allergic treatments was added to the Egyptian approved drugs list in 2015 with total sales of EGP 130 million. These stops brought our overall sales from locally produced treatments to EGP 430 million annually in October 2022,” Wanis explained.
He referred to the partnership between his company and the Egyptian Drug Authority that includes manufacturing 60-70 percent of Bayer’s consumer products over the coming three years, with total investments worth EGP 240 million.
Bayer has future plans to meet the Egyptian market's tendency to export to neighbouring countries, according to Wanis.
He said that imported drugs make up seven percent of the Egyptian drugs market.
The cascading crises, including the COVID-19 pandemic and the Russian-Ukrainian conflict, have affected the global economy; including the pharma industry, in terms of the shortage of hard currency to meet importing needs, he continued.
Wanis pointed to the public-private partnerships as a key and vital actor that helped provide imported drugs for Egyptian patients.
Short link: